Alnylam Pharmaceuticals price target maintained at $455 by HC Wainwright
HC Wainwright & Co. maintained a $455.00/share price target on Alnylam Pharmaceuticals, according to Benzinga.
HC Wainwright & Co. maintained a $455.00/share price target on Alnylam Pharmaceuticals, according to Benzinga.